CBD Pet Products - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The cBD pet products market size is USD 339.74 million in 2026 and is projected to reach USD 504.11 million by 2031, advancing at an 8.21% CAGR over the forecast period. This report is Segmented by Type (Food-Grade and Therapeutic-Grade), by Animal Type (Dog, Cat, and Other Pets), by Distribution Channel (Online Retail Channels, Retail Pharmacies, Veterinary Clinics, and Other Distribution Channels), and by Geography (North America, Europe, Asia-Pacific, South America, and Africa). The Market Forecasts are Provided in Terms of Value (USD).

Global CBD Pet Products Market Trends and Insights

Increasing Incidence of Chronic Disorders in Pets

Degenerative joint disease, epilepsy, and anxiety now afflict a sizable share of aging companion animals, prompting sustained demand for non-pharmaceutical interventions. Owners worry about the hepatotoxicity of long-term NSAID use and are turning to cannabinoid-based solutions that interact with CB1 and CB2 receptors. Clinical trials reported a 35% pain-score reduction in osteoarthritic dogs given full-spectrum CBD at 2 mg/kg twice daily, without liver-enzyme elevation. These outcomes nurture veterinary confidence and widen prescriptive adoption. The trend is especially evident in North America, where 40% of dogs aged seven years or older exhibit chronic arthritis symptoms. Parallel patterns emerge across Europe, positioning CBD as a bridge therapy for refractory conditions. The resulting uptick in daily dosing drives repeat purchases and strengthens lifetime customer value.

Rising Pet Ownership and Humanization Trends

In 2024, 67% of American households owned at least one pet, marking a significant increase from 2021. Millennials and Gen Z lead this expansion and treat animals as family, allocating monthly budgets of USD 60-120 for CBD treats in lieu of generic supplements costing one-third as much. Comparable sentiment in Germany, where pet ownership penetration reached 47% in 2024, reinforces tolerance for premium pricing. These consumers actively research ingredients, prefer organic hemp, and reward brands that publish batch-level potency tests. Social media amplifies personal testimonials, normalizing cannabidiol as a preventive wellness tool. As owners adopt adaptogen habits for their pets, demand for USDA-certified CBD tinctures increases across metropolitan areas worldwide.

High Cost of Premium CBD Pet Products

Full-spectrum organic CBD oils retail at USD 0.15-0.25 per milligram, roughly triple the cost of glucosamine-chondroitin supplements, creating affordability barriers in emerging economies. A month-long CBD regimen for a medium-sized dog can be costly, positioning cannabidiol as a discretionary luxury rather than a staple. Upstream expenses include certified-organic cultivation, supercritical CO₂ extraction, and batch-level contaminant screening, all of which contribute significantly to production costs. When regulators do not mandate testing, price-sensitive owners often choose cheaper, uncertified products or abandon CBD altogether. Consequently, penetration remains low across South America and Africa, where disposable incomes are constrained. Persistent cost differentials in the CBD pet products market temper volume growth despite rising global awareness.

Other drivers and restraints analyzed in the detailed report include:

• Increased Focus and Expenditure on Pet Health and Wellness
• Expanding Retail and E-Commerce Channels That Allow CBD Sales
• Stringent Regulatory Requirements for Product Approval

Segment Analysis

Therapeutic-grade oils captured 55% of the 2025 value, followed by food-grade treats, while personal-care topicals accounted for the remainder. Concentrated tinctures with 300-1,500 mg cannabidiol per bottle lead the CBD pet products market because they allow weight-based dose titration. Food-grade chews maintain share by masking hemp taste, yet they suffer lower bioavailability. Topicals remain niche but appeal to owners treating localized dermatitis without oral administration.

Therapeutic-grade oils will post a 15.4% CAGR through 2031, the fastest within the category, propelled by nano-emulsion technologies that cut onset time to 15 minutes. Food-grade treats are estimated to grow strongly, supported by new flavors and soft-chew formats. Topicals are also projected to expand steadily as veterinary dermatology increasingly embraces cannabinoid-infused shampoos and balms.

Complete Report Scope:

• By Type
  • Food-grade
  • Therapeutic-grade
• By Animal Type
  • Dog
  • Cat
  • Other pets
• By Distribution Channel
  • Online retail channel
  • Retail pharmacies and pet stores
  • Veterinary clinics
  • Other channels
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • United Kingdom
    • France
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Africa
    • South Africa
    • Rest of Africa

Geography Analysis

North America generated 48% of 2025 revenue and is estimated to continue expanding at a strong pace. United States households spend an average of USD 1,480 per pet annually and readily adopt organic CBD oils endorsed by veterinarians. Canada’s 2024 Cannabis Act amendments removed pre-market hurdles for hemp-derived pet products, letting provincial chains stock CBD alongside traditional supplements. Mexico is estimated to issue formal guidelines by 2027, unlocking pent-up demand currently served through gray imports.

Asia-Pacific is forecast to grow at 15.1% CAGR, the highest among all regions. Australia reclassified low-THC CBD as Schedule 4 in 2025, enabling prescription fulfillment through pharmacies and fueling immediate volume gains. China’s draft hemp-supplement regulations signal market opening in a country with rising middle-class expenditure and pet population. India awaits Food Safety and Standards Authority clarity, yet rising urban pet ownership is flagging a latent market opportunity once rules crystallize.

Europe will advance at a strong pace. Germany, the United Kingdom, France, and Spain together represent the majority of regional spend. Stricter Veterinary Medicines Directorate rules in the United Kingdom slow product launches but elevate overall quality standards, while Germany’s guidance excluding low-THC hemp extracts from narcotic regulations streamlines distribution. South America is also estimated to expand steadily, led by Brazil’s over-the-counter approval framework for CBD pet oils. Africa remains a nascent market, while South Africa’s prescription-only stance confines distribution primarily to licensed veterinary practices.

List of Companies Covered in this Report:

• Charlotte's Web, Inc.
• cbdMD
• Pet Releaf
• Honest Paws
• Holista LLC
• Joy Organics
• HempMy Pet
• Canna-Pet
• Fomo Bones
• Swedencare (NaturVet)
• Balanced Health Botanicals (CBDistillery)
• Medterra
• The Valens Company Inc. (Green Roads)
• Innovet Pet
• King Kanine

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support